Pharmacomodulation of high-density lipoprotein metabolism as a therapeutic intervention for atherosclerotic disease

Current Cardiology Reports

Volumn 12, Issue 6, 2010, Pages 481-487

  Toth, Peter P ^a  

^a Sterling Rock Falls Clinic ^*  (United States)

Author keywords

Cholesterol ester transfer protein; D 4F; High density lipoprotein; Laropiprant; Liver X receptor agonist; Reverse cholesterol transport

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ANACETRAPIB; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CSL 111; D 4F; DALCETRAPIB; ETC 216; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN RECEPTOR; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; R 138239; RVX 208; TORCETRAPIB; TREDAPTIVE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BICARBONATE BLOOD LEVEL; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME ACTIVITY; EXPERIMENTAL ANIMAL; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; NONHUMAN; PROTEIN FUNCTION; PRURITUS; REVIEW; RISK REDUCTION; SEX DIFFERENCE; SIDE EFFECT;

ANIMALS; ARTERIOSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; HUMANS; HYPOLIPIDEMIC AGENTS; INDOLES; LIPID METABOLISM; RISK ASSESSMENT; RISK FACTORS;

EID: 77958476362     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-010-0136-3     Document Type: Review

References (52)

1. Expert Panel on Detection 2001 Evaluation, and Treatment of High Blood Cholesterol in Adults003A Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2486 2497 10.1001/jama.285.19.2486
2. BM Psaty M Anderson RA Kronmal, et al. 2004 The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: the Cardiovascular Health Study J Am Geriatr Soc 52 1639 1647 10.1111/j.1532-5415.2004.52455.x 15450039 (Pubitemid 41709916)
3. WP Castelli 1988 Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study Can J Cardiol 4 5A 10A 3179802
4. G Walldius I Jungner I Holme, et al. 2001 High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study Lancet 358 2026 2033 1:CAS:528:DC%2BD38XhsFSn 10.1016/S0140-6736(01)07098-2 11755609 (Pubitemid 34084825)
5. Y Cui DJ Watson CJ Girman, et al. 2009 Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study) Am J Cardiol 104 829 834 1:CAS:528: DC%2BD1MXhtV2rt7%2FE 10.1016/j.amjcard.2009.05.020 19733719 This is an important post hoc analysis from the AFCAPS/TexCAPS trial demonstrating that even a minimal increase in HDL-C correlates with significant cardiovascular risk reduction in the primary care setting
6. CM Ballantyne JA Herd LL Ferlic, et al. 1999 Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy Circulation 99 736 743 1:CAS:528:DyaK1MXhsFCntbY%3D 9989957
7. I Goldenberg U Goldbourt V Boyko, et al. 2006 Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial) Am J Cardiol 97 466 471 1:CAS:528: DC%2BD28Xhtlaqt7w%3D 10.1016/j.amjcard.2005.09.078 16461038 (Pubitemid 43190032)
8. SJ Robins 2001 Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial Am J Cardiol 88 19N 23N 1:CAS:528:DC%2BD38XitlWgug%3D%3D 10.1016/S0002-9149(01)02148-8 11788126
9. CM Ballantyne JS Raichlen SJ Nicholls, et al. 2008 Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden Circulation 117 2458 2466 1:CAS:528:DC%2BD1cXltl2hsb8%3D 10.1161/CIRCULATIONAHA.108.773747 18378607 (Pubitemid 351670452)
10. SJ Nicholls EM Tuzcu I Sipahi, et al. 2007 Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis JAMA 297 499 508 1:CAS:528:DC%2BD2sXhs1Wis7k%3D 10.1001/jama.297.5.499 17284700 This is a landmark analysis showing that coronary atheroma regression detected by IVUS is dependent on a coupling of LDL-C reduction and HDL-C elevation (Pubitemid 46220805)
11. B Brown X Zhao M Cheung 2007 Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence J Clin Lipidol 1 88 94 10.1016/j.jacl.2007.02.004 (Pubitemid 46710835)
12. T Vaisar S Pennathur PS Green, et al. 2007 Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL J Clin Invest 117 746 756 1:CAS:528:DC%2BD2sXis12htLs%3D 10.1172/JCI26206 17332893 This is a seminal study revealing the enormous complexity of the HDL proteosome (Pubitemid 46348533)
13. PP Toth 2003 Reverse cholesterol transport: high-density lipoprotein's magnificent mile Curr Atheroscler Rep 5 386 393 10.1007/s11883-003-0010-5 12911849
14. JR Nofer G Assmann 2005 Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids Trends Cardiovasc Med 15 265 271 1:CAS:528:DC%2BD2MXhtFWhtL%2FN 10.1016/j.tcm.2005.08.005 16226682 (Pubitemid 41437910)
15. JR Nofer B Levkau I Wolinska, et al. 2001 Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids J Biol Chem 276 34480 34485 1:CAS:528:DC%2BD3MXmvFClsbg%3D 10.1074/jbc.M103782200 11432865
16. JR Nofer M van der Giet M Tolle, et al. 2004 HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3 J Clin Invest 113 569 581 1:CAS:528:DC%2BD2cXhsFKhsbg%3D 14966566
17. P Barter AM Gotto JC LaRosa, et al. 2007 HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 1301 1310 1:CAS:528:DC%2BD2sXhtFSmtr3M 10.1056/NEJMoa064278 17898099 (Pubitemid 47481452)
18. EM deGoma NJ Leeper PA Heidenreich 2008 Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol J Am Coll Cardiol 51 49 55 1:CAS:528: DC%2BD1cXislCruw%3D%3D 10.1016/j.jacc.2007.07.086 18174036 This is an important study that demonstrated that even with LDL-C less than 60 mg/dL, a low serum level of HDL-C was associated with increased risk for CAD-related events
19. PJ Barter JJ Kastelein 2006 Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease J Amer Coll Cardiol 47 492 499 1:CAS:528:DC%2BD28XhtVGjs7k%3D 10.1016/j.jacc.2005.09.042 (Pubitemid 43170835)
20. SE Nissen JC Tardif SJ Nicholls, et al. 2007 Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 1304 1316 1:CAS:528:DC%2BD2sXjsFGnsrY%3D 10.1056/NEJMoa070635 17387129 (Pubitemid 46513296)
21. SJ Nicholls EM Tuzcu DM Brennan, et al. 2008 Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) Circulation 118 2506 2514 1:CAS:528:DC%2BD1cXhsVerur3L 10.1161/CIRCULATIONAHA.108.790733 19029466
22. JJ Kastelein SI van Leuven L Burgess, et al. 2007 Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 1620 1630 1:CAS:528:DC%2BD2sXksFCmsb4%3D 10.1056/NEJMoa071359 17387131 (Pubitemid 46631671)
23. ML Bots FL Visseren GW Evans, et al. 2007 Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 370 153 160 1:CAS:528:DC%2BD2sXns12jtLg%3D 10.1016/S0140-6736(07)61088-5 17630038 (Pubitemid 47042895)
24. PJ Barter M Caulfield M Eriksson, et al. 2007 Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2109 2122 1:CAS:528:DC%2BD2sXhtlGns7bL 10.1056/NEJMoa0706628 17984165 (Pubitemid 350146106)
25. L Yvan-Charvet F Matsuura N Wang, et al. 2007 Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL Arterioscler Thromb Vasc Biol 27 1132 1138 1:CAS:528: DC%2BD2sXktFagtLs%3D 10.1161/ATVBAHA.106.138347 17322101 (Pubitemid 46641969)
26. EA Stein ES Stroes G Steiner, et al. 2009 Safety and tolerability of dalcetrapib Am J Cardiol 104 82 91 1:CAS:528:DC%2BD1MXotFCitL8%3D 10.1016/j.amjcard.2009.02.061 19576325
27. R Krishna MS Anderson AJ Bergman, et al. 2007 Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies Lancet 370 1907 1914 1:CAS:528:DC%2BD2sXhsVShtLrE 10.1016/S0140-6736(07)61813-3 18068514 (Pubitemid 350192656)
28. JJ Badimon L Badimon V Fuster 1990 Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J Clin Invest 85 1234 1241 1:CAS:528:DyaK3cXitlehtbw%3D 10.1172/JCI114558 2318976
29. S Ameli A Hultgardh-Nilsson B Cercek, et al. 1994 Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits Circulation 90 1935 1941 1:CAS:528: DyaK2MXhvFOgsbo%3D 7923682
30. RK Tangirala K Tsukamoto SH Chun, et al. 1999 Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice Circulation 100 1816 1822 1:CAS:528:DyaK1MXntl2gsLY%3D 10534470 (Pubitemid 29498389)
31. SE Nissen T Tsunoda EM Tuzcu, et al. 2003 Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2292 2300 1:CAS:528:DC%2BD3sXovVCjtbc%3D 10.1001/jama.290.17.2292 14600188 (Pubitemid 37430562)
32. JC Tardif J Gregoire PL L'Allier, et al. 2007 Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 1675 1682 10.1001/jama.297.15.jpc70004 17387133 (Pubitemid 46631626)
33. FM Sacks LL Rudel A Conner, et al. 2009 Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo J Lipid Res 50 894 907 1:CAS:528:DC%2BD1MXkvVSnu7k%3D 10.1194/jlr.M800622-JLR200 19144994
34. D Bailey R Jahagirdar A Gordon, et al. 2010 RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo J Am Coll Cardiol 55 2580 2589 1:CAS:528:DC%2BC3cXptV2msr0%3D 10.1016/j.jacc.2010.02.035 20513599 This paper discusses a remarkable leap in apo A-I therapeutics demonstrating that an orally bioavailable small molecule drug stimulates hepatic apo A-I expression, macrophage cholesterol efflux, and ndHDL formation in humans
35. T Nishizawa K Kitayama K Wakabayashi, et al. 2007 A novel compound, R-138329, increases plasma HDL cholesterol via inhibition of scavenger receptor BI-mediated selective lipid uptake Atherosclerosis 194 300 308 1:CAS:528:DC%2BD2sXhtFerurrK 10.1016/j.atherosclerosis.2006.10.025 17166497 (Pubitemid 47513091)
36. B Trigatti S Covey A Rizvi 2004 Scavenger receptor class B type I in high-density lipoprotein metabolism, atherosclerosis and heart disease: lessons from gene-targeted mice Biochem Soc Trans 32 Pt 1 116 120 1:CAS:528: DC%2BD2cXisVGrtL0%3D 10.1042/BST0320116 14748727 (Pubitemid 38283028)
37. B Staels JC Fruchart 2005 Therapeutic roles of peroxisome proliferator-activated receptor agonists Diabetes 54 2460 2470 1:CAS:528:DC%2BD2MXnt1ynt7Y%3D 10.2337/diabetes.54.8.2460 16046315 (Pubitemid 41134276)
38. G Chinetti S Lestavel V Bocher, et al. 2001 PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway Nat Med 7 53 58 1:CAS:528: DC%2BD3MXmvFShtg%3D%3D 10.1038/83348 11135616 (Pubitemid 32095642)
39. G Chinetti-Gbaguidi E Rigamonti L Helin, et al. 2005 Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages J Lipid Res 46 2717 2725 1:CAS:528:DC%2BD2MXhtlWmsb7P 10.1194/jlr.M500326-JLR200 16162941 (Pubitemid 43107484)
40. JC Fruchart 2007 Novel peroxisome proliferator activated receptor-alpha agonists Am J Cardiol 100 n41 n46 10.1016/j.amjcard.2007.08.012 18047852 (Pubitemid 350151383)
41. SU Naik X Wang JS Da Silva, et al. 2006 Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo Circulation 113 90 97 1:CAS:528:DC%2BD2MXhtlCrtbnE 10.1161/CIRCULATIONAHA.105.560177 16365197 (Pubitemid 43958493)
42. M Pal S Pillarisetti 2007 HDL elevators and mimetics-emerging therapies for atherosclerosis Cardiovasc Hematol Agents Med Chem 5 55 66 1:CAS:528:DC%2BD2sXisVyiu70%3D 17266548
43. AC Li CK Glass 2004 PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis J Lipid Res 45 2161 2173 1:CAS:528:DC%2BD2MXhtVOitA%3D%3D 10.1194/jlr.R400010-JLR200 15489539 (Pubitemid 39602963)
44. JP Segrest L Li GM Anantharamaiah, et al. 2000 Structure and function of apolipoprotein A-I and high-density lipoprotein Curr Opin Lipidol 11 105 115 1:CAS:528:DC%2BD3cXislWjs7Y%3D 10.1097/00041433-200004000-00002 10787171 (Pubitemid 30219104)
45. X Li KY Chyu JR Faria Neto, et al. 2004 Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice Circulation 110 1701 1705 1:CAS:528: DC%2BD2cXnsVKqu74%3D 10.1161/01.CIR.0000142857.79401.69 15353488 (Pubitemid 39297996)
46. M Navab GM Anantharamaiah ST Reddy, et al. 2005 Apolipoprotein A-I mimetic peptides Arterioscler Thromb Vasc Biol 25 1325 1331 1:CAS:528: DC%2BD2MXltlSju70%3D 10.1161/01.ATV.0000165694.39518.95 15831812 (Pubitemid 40923347)
47. GM Anantharamaiah VK Mishra DW Garber, et al. 2007 Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides J Lipid Res 48 1915 1923 1:CAS:528:DC%2BD2sXpslOjurk%3D 10.1194/jlr.R700010-JLR200 17570869 (Pubitemid 47360611)
48. Clofibrate and niacin in coronary heart disease [no authors listed]. JAMA 1975, 231:360-381.
49. BG Brown XQ Zhao A Chait, et al. 2001 Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 1583 1592 1:CAS:528:DC%2BD3MXoslyhsLs%3D 10.1056/NEJMoa011090 11757504 (Pubitemid 33126837)
50. K Cheng TJ Wu KK Wu, et al. 2006 Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans Proc Natl Acad Sci U S A 103 6682 6687 1:CAS:528:DC%2BD28XksVKrtLY%3D 10.1073/pnas.0601574103 16617107
51. JF Paolini YB Mitchel R Reyes, et al. 2008 Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia Am J Cardiol 101 625 630 1:CAS:528:DC%2BD1cXislams7Y%3D 10.1016/j.amjcard.2007.10.023 18308010 Laropiprant effectively reduces niacin-induced flushing and significantly increases compliance with niacin therapy without blunting the therapeutic efficacy of the drug on lipid parameters (Pubitemid 351625086)
52. D Maccubbin HE Bays AG Olsson, et al. 2008 Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia Int J Clin Pract 62 1959 1970 1:CAS:528:DC%2BC3cXktFGntrc%3D 10.1111/j.1742-1241.2008.01938.x 19166443